PORTEC 3, 2018 Flashcards
1
Q
Study question of PORTEC-3?
A
Is chemoRT better than RT alone for HR EC
2
Q
Study design of PORTEC3?
A
RCT randomly allocated (1:1) to RT (48.6 Gy in 1.8 Gy fractions) or CTRT (two cycles of cisplatin 50 mg/m² in week 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m² at 3-week intervals) with stratification for participating center, lymphadenectomy, stage, and histological type; OS and FFS
3
Q
Results of PORTEC3?
A
n=686 from 2006-2013
3y OS CTRT/ RT: 84 and 84%
3y FFS CTRT /RT: 75 and 69%
at 5y Stage II with lower 5y FFS r/t 1-2 and benefit most from CTRT (70% vs 60% for RT)
